Targeting myelogenous leukemia stem cells: role of the circulation.

摘要: Unlike stem cells from solid tumors, the which initiate myelogenous leukemias arise in marrow, an organ with a unique circulation allows ready access of leukemia cells, including (LSCs), to vasculature. This poses problems targeting LSCs since these are found circulating majority cases at diagnosis and usually not detectable during remission states. Because most relapse, it is suggested that remain quiescent marrow until they eventually proliferate circulate again. indicates effective must occur only peripheral but micro-circulation marrow. Targeting such interactions may overcome cell adhesion-mediated treatment resistance, other multi-drug resistance mechanisms, opportunities for clonal evolution environment. selectins integrins, signal transduction mediators, chemokine/cytokine networks aid abrogating leukemia-initiating contribute disease relapse. possess surface antigen profiles activation allow differential as compared normal hematopoietic cells.